High Throughput Genomics Signs Collaboration Agreement with University of California, San Diego
News Sep 11, 2007
Under the terms of the agreement, HTG and UCSD will collaborate to generate arrays using tissue samples from mice as well as various cell lysates to evaluate genes responsible for inflammation and insulin production using HTG’s qNPA™ quantitative Nuclease Protection Assay technology. Dr. Jerry Olefsky is the lead collaborator on the project for UCSD.
One of the key goals for this research program is to study mechanisms of insulin resistance and how inflammation is involved in the pathogenesis of diabetes. Having genes on the array that are markers for inflammation is an effective way for UCSD to assess biomarkers and study the genes in question.
“We are excited about the utility of HTG’s technology platform for a number of reasons including cost effectiveness and time savings by having multiple genes analyzed simultaneously,” said Dr. Jerry Olefsky. “The reliability and reproducibility of the technology will enable our research team to move through our project with great ease and confidence.”
HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE
Is there a link between differences in IQ test performance and the activity of certain genes? Researchers have shown that modifications in the structure of a specific gene have a negative impact on individual test performance. This suggests that environmentally-induced epigenetic changes to our genetic material have a greater impact on intelligence than previously thought.